Showing 1501-1510 of 1614 results for "".
- UK Regulator Unconditionally Clears Roche’s Purchase of Spark Therapeuticshttps://modernod.com/news/uk-regulator-unconditionally-clears-roches-purchase-of-spark-therapeutics/2477170/The UK Competition and Markets Authority (CMA) announced Monday the clearance of Roche’s proposed purchase of Spark Therapeutics after concluding that the deal would not negatively affect competition for haemophilia A treatments. The Swiss drugmaker noted that the offer period under the tra
- AI Diagnostics Company IDx Announces New Appointments to its Executive Leadership Teamhttps://modernod.com/news/ai-diagnostics-company-idx-announces-new-appointments-to-its-executive-leadership-team/2477153/IDx Technologies announced several new appointments to its executive leadership team to accelerate product development and scale operations to accommodate increased market adoption of IDx-DR, according to a company news release. IDx-DR is an FDA-authorized autonomous AI system that detects diabet
- RightEye Vision System Receives Breakthrough Device Designation from the FDA for Parkinson’s Disease Testhttps://modernod.com/news/righteye-vision-system-receives-breakthrough-device-designation-from-the-fda-for-parkinsons-disease-test/2477133/RightEye announced that the RightEye Vision System has received breakthrough device designation from the FDA for a Parkinson’s Disease Test. The designation is designed to streamline the market clearance
- Aerie Pharmaceuticals Receives European Commission Approval for Glaucoma Drug Rhokiinsahttps://modernod.com/news/aerie-pharmaceuticals-receives-european-commission-approval-for-glaucoma-drug-rhokiinsa/2477111/Aerie Pharmaceuticals announced the European Commission (EC) has granted a marketing authorization for Rhokiinsa (netarsudil ophthalmic solution) 0.02% for the reduction of elevated IOP in adult patients with primary open-angle glaucoma or ocular hypertension. The marketing authorization a
- Report: Novartis Weighing Takeover Offer for The Medicines Companyhttps://modernod.com/news/report-novartis-weighing-takeover-offer-for-the-medicines-company/2477107/Novartis is considering making an offer to acquire The Medicines Company and is currently conducting due diligence on the drugmaker, Bloomberg reported Tuesday, citing people close to the matter. The sources suggested that The Medicines Company, which has a market value of about $4.7 bi
- ELT Sight Acquires Assets and IP of MLase AG Excimer Ophthalmic Laser System for Glaucoma Surgeryhttps://modernod.com/news/elt-sight-acquires-assets-and-ip-of-mlase-ag-excimer-ophthalmic-laser-system-for-glaucoma-surgery/2477086/ELT Sight announced the company has acquired the IP and assets of MLase AG’s excimer ophthalmic laser system for glaucoma surgery. Terms for the acquisition were not disclosed. MLase manufactures and markets laser systems, including the ExTra ELT Laser and disposable applicator used
- Oyster Point Pharma Announces Pricing of Initial Public Offeringhttps://modernod.com/news/oyster-point-pharma-announces-pricing-of-initial-public-offering/2477064/Oyster Point Pharma announced the pricing of its initial public offering of 5,000,000 shares of its common stock at a price to the public of $16.00 per share. The shares began trading on The Nasdaq Global Select Market on October 31, 2019 under the symbol “OYST.” All of the shares ar
- Manufacturers, Providers Increasingly Rely on Premium Cataract Surgery Revenuehttps://modernod.com/news/manufacturers-providers-increasingly-rely-on-premium-cataract-surgery-revenue/2477057/The importance of premium cataract surgery to manufacturers, surgeons, and surgery centers alike grows, as reimbursements for cataract surgery under nationalized health care systems worldwide continue to decline, according to a Market Scope report. The reduction in cataract surgery reimbur
- FDA Accepts Genentech’s Biologics License Application for Satralizumab for Neuromyelitis Optica Spectrum Disorderhttps://modernod.com/news/fda-accepts-genentechs-biologics-license-application-for-satralizumab-for-neuromyelitis-optica-spectrum-disorder/2477055/Genentech announced the FDA has accepted the company’s biologics license application (BLA) for satralizumab for the treatment of adults and adolescents with neuromyelitis optica spectrum disorder (NMOSD). The European Medicines Agency (EMA) has also validated the company’s Marketing Authorization
- IDx Taps Former LabCorp Executive to Lead Sales and Customer Successhttps://modernod.com/news/idx-taps-former-labcorp-executive-to-lead-sales-and-customer-success/2477030/IDx Technologies announced that it has appointed former LabCorp executive Seth Rainford as President of Global Markets. In his newly created role, Mr. Rainford will be charged with expanding market opportunities and driving operational excellence at IDx. “Se